MPO and bacterial vaginosis: Even though this study cannot be used to draw any conclusions about therapeutic potential, Jang et al. modified the procedure used in a bacterial vaginosis animal study and discovered that Respecta®, when administered orally or intravaginally, attenuated Gardnerella vaginalis-induced bacterial vaginosis by reducing epithelial cell disruption and myeloperoxidase activity [28].